Trends and Innovations in Patient Adherence
Taking the right dose of the right medicine at the right time is key to improving health outcomes, so why do so many patients fail to adhere to their treatment programme?
Trends and Innovations in Patient Adherenceis a thought-provoking and comprehensive report for everyone involved in ensuring patients comply with taking their medicines. The report provides extensive background information and is enriched by case studies. Most importantly, the report reveals the candid opinions of 16 leading experts from the pharma industry, health payers and patient advocacy groups in the US and Europe that present business-critical insights for pharma.
If one issue unites health payers, clinicians and the pharma industry, it is patient adherence. Clinicians want the best possible outcome for their patients, health payers need to ensure health spending is optimised and the industry wants clinical outcomes to reflect the safety and efficacy seen in trials. However a number of patients decide - for a variety of reasons – not to take their medicines as directed. The consequential cost of poor patient adherence is considerable, and changing behaviours is proving a challenge.
How can pharma improve its education and patient adherence programmes? What role can patient advocacy groups play? How do health payers assess value for money? What part could technological innovations play in modifying patient behaviour? Get answers to these questions in this new report.
Key Benefits
Pharma
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Trends and Innovations in Patient Adherenceis a thought-provoking and comprehensive report for everyone involved in ensuring patients comply with taking their medicines. The report provides extensive background information and is enriched by case studies. Most importantly, the report reveals the candid opinions of 16 leading experts from the pharma industry, health payers and patient advocacy groups in the US and Europe that present business-critical insights for pharma.
If one issue unites health payers, clinicians and the pharma industry, it is patient adherence. Clinicians want the best possible outcome for their patients, health payers need to ensure health spending is optimised and the industry wants clinical outcomes to reflect the safety and efficacy seen in trials. However a number of patients decide - for a variety of reasons – not to take their medicines as directed. The consequential cost of poor patient adherence is considerable, and changing behaviours is proving a challenge.
How can pharma improve its education and patient adherence programmes? What role can patient advocacy groups play? How do health payers assess value for money? What part could technological innovations play in modifying patient behaviour? Get answers to these questions in this new report.
Key Benefits
- Understand the many and diverse drivers of patient non-compliance behaviour
- Formulate strategies to improve adherence in specific patient groups
- Assess the attitudes of health payers to non-adherence and identify collaborative opportunities to tackle it
- Learn of multi-functional approaches to creating effective adherence programmes
- Appreciate the importance of monitoring outcomes to support programmes and encourage use
- Understand the technical innovations that will underpin drives to improve adherence and monitoring
- Plan effective patient adherence programmes to ensure support is appropriate and sustained
- What is the current understanding of the clinical, social, economic and personal factors that lead to poor patient adherence?
- Is patient adherence all about the cost for health payers, and how do payers view current patient adherence programmes? How might patient non-adherence influence product strategies and research programmes?
- What are the benefits of industry, patient groups and clinicians working together to develop optimal approaches for both acute and chronic conditions?
- Digital innovations such as messaging reminders, electronic pill dispensers and smart pills can improve adherence and provide clinical feedback – where, how and when might they be used for best advantage?
- What are the critical success factors for patient adherence programmes, and how will they evolve in the near future?
- Learn the views and needs of health payers and patient groups when formulating patient education and support programmes
- Review case studies on how industry is tackling the challenges
- Identify the key behavioural drivers that lead to patient non adherence
- Appreciate how digital innovation will influence this key area of industry
- Key recommendations to maximise success of adherence programmes
- Knowledgeable and detailed “real world” opinions of 16 leading experts working daily in the patient adherence field across the US and Europe
- Illustrative case studies demonstrating different approaches
- A thought provoking assessment of the challenges for tackling patient non-compliance and how views in Europe and US differ
- Critical insights for planning, marketing, brand management and stakeholder engagement
Pharma
- European medical affairs manager at a global biopharmaceutical company
- European marketing manager at a global pharmaceutical company
- Global marketing manager at a major pharmaceutical company
- Head of patient engagement, European pharmaceutical company
- Pharmacy director at a national health insurer, US
- Chief medical officer, managed care organisation (MCO), US
- Vice president of a national pharmacy benefits manager (PBM), US
- Medicines optimisation and prescribing lead at a large NHS clinical commissioning group (CCG), UK
- Pharmacy director, France
- Chief pharmacist, Italy
- Chief pharmacist, Spain
- Anonymous German KOL
- Director, European Patients’ Academy on Therapeutic Innovation (EUPATI)
- Board member of the European Parkinson’s Disease Association (EPDA)
- Chief Executive of a myeloma support organisation
- Founder and president of online community and resource centre for cancer patients, survivors and families
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
- FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. FirstWord Reports provide expert views and intelligence on the challenges facing pharma today in these topic areas: Biosimilars, Market Access, Medical Affairs, Sales & Marketing, Technology, Therapy Areas.
- FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
1.EXECUTIVE SUMMARY
There are wide-ranging factors for patient non-adherence
The pharmaceutical industry is investigating several different ways to address non-adherence
Patient adherence programmes can provide valuable support
Innovative technologies are being used to address non-adherence
2. RESEARCH OBJECTIVES AND METHODOLOGY
3. CONTRIBUTORS
4.1.Patient adherence overview
4.2.Adherence versus compliance
4.3.Pharma definitions of adherence
4.4.Payer definitions of adherence
4.5.Patient adherence is important for payers, pharma and patients
4.6.The importance of adherence from a pharma perspective
4.7.The importance of adherence from a payer perspective
4.8.Impacts of non-adherence
4.9.Rates of non-adherence vary between countries, diseases and populations
4.10.Non-adherence affects morbidity and mortality
4.11.The financial impact of non-adherence
4.12.Payer views on the impact of non-adherence
4.13.The impact of non-adherence from a pharma perspective
4.14.Reasons for non-adherence
4.15.Health system factors
4.16.Social and economic factors
4.17.Condition-related factors
4.18.Therapy-related factors
4.19.Patient-related factors
4.20.Non-adherence among specific patient populations
4.21.Adherence concerns for HIV and Hepatitis C
4.22.The challenge of asymptomatic and acute patients
4.23.Pharma views on adherence and product strategy
4.24.Payer perspectives on the importance of adherence
4.25.Adherence considerations can affect payer decisions
4.26.The difficulty of measuring adherence
5.ADHERENCE PROGRAMMES
5.1.Pharma views on adherence programmes
5.2.Patient views on support programmes
5.3.Payer views on patient support programmes
5.4.Payer views on pharma-sponsored programmes
5.5.Stakeholder involvement in programme development from a pharma perspective
5.6.Payer views on programme development
5.7.Challenges with adherence programmes
5.8.The regulatory and legal environment means programmes can be inflexible
5.9.Adherence programmes have been slow to embrace advanced technology
5.10.Pharma-sponsored programmes have a limited lifespan
5.11.Key success factors for adherence programmes
5.12.Individualising content makes programmes more valuable
5.13.Programmes that generate outcomes data are more useful for stakeholders
5.14.Optimising the use of digital technology is key for successful programmes
5.15.Maintain independence to improve credibility
5.16.Programme design is of critical importance
5.17.A more holistic approach to adherence programmes
5.18.Consider the limited impact of programmes on decision-making
5.19.Examples of successful programmes
5.20.BMS has demonstrated successful collaboration
5.21.Novartis: bridging the gap between different countries
5.22.Adherence programmes can require proactive measures
5.23.It can be effective to pre-empt the reasons for non-adherence
6.TECHNOLOGICAL ADVANCES IN ADHERENCE MANAGEMENT
6.1.Different technologies to enhance patient adherence
6.2.Internet-based medication support
6.3.Reminder services
6.4.Smartphone apps
6.5.Electronic pill dispensers
6.6.Smart pills
6.7.The cost-benefit of new innovations needs to be proven
6.8.Innovative technology may go some way towards addressing adherence but is not a complete solution
7.FUTURE DIRECTION FOR PATIENT ADHERENCE
7.1.How will adherence strategies evolve?
7.2.There are unmet needs for improving adherence
7.3.Innovative approaches to adherence are anticipated
7.4.Improvements in devices and delivery mechanisms would aid adherence
7.5.Recommendations for pharma companies
7.6.Education is vital to improve adherence
7.7.Listen to external stakeholders
7.8.Take a long-term view
7.9.Including outcomes as part of adherence programmes will make them more valuable
7.10.Harness knowledge and experience from external providers
7.11.Early planning will help to guarantee success
There are wide-ranging factors for patient non-adherence
The pharmaceutical industry is investigating several different ways to address non-adherence
Patient adherence programmes can provide valuable support
Innovative technologies are being used to address non-adherence
2. RESEARCH OBJECTIVES AND METHODOLOGY
3. CONTRIBUTORS
4.1.Patient adherence overview
4.2.Adherence versus compliance
4.3.Pharma definitions of adherence
4.4.Payer definitions of adherence
4.5.Patient adherence is important for payers, pharma and patients
4.6.The importance of adherence from a pharma perspective
4.7.The importance of adherence from a payer perspective
4.8.Impacts of non-adherence
4.9.Rates of non-adherence vary between countries, diseases and populations
4.10.Non-adherence affects morbidity and mortality
4.11.The financial impact of non-adherence
4.12.Payer views on the impact of non-adherence
4.13.The impact of non-adherence from a pharma perspective
4.14.Reasons for non-adherence
4.15.Health system factors
4.16.Social and economic factors
4.17.Condition-related factors
4.18.Therapy-related factors
4.19.Patient-related factors
4.20.Non-adherence among specific patient populations
4.21.Adherence concerns for HIV and Hepatitis C
4.22.The challenge of asymptomatic and acute patients
4.23.Pharma views on adherence and product strategy
4.24.Payer perspectives on the importance of adherence
4.25.Adherence considerations can affect payer decisions
4.26.The difficulty of measuring adherence
5.ADHERENCE PROGRAMMES
5.1.Pharma views on adherence programmes
5.2.Patient views on support programmes
5.3.Payer views on patient support programmes
5.4.Payer views on pharma-sponsored programmes
5.5.Stakeholder involvement in programme development from a pharma perspective
5.6.Payer views on programme development
5.7.Challenges with adherence programmes
5.8.The regulatory and legal environment means programmes can be inflexible
5.9.Adherence programmes have been slow to embrace advanced technology
5.10.Pharma-sponsored programmes have a limited lifespan
5.11.Key success factors for adherence programmes
5.12.Individualising content makes programmes more valuable
5.13.Programmes that generate outcomes data are more useful for stakeholders
5.14.Optimising the use of digital technology is key for successful programmes
5.15.Maintain independence to improve credibility
5.16.Programme design is of critical importance
5.17.A more holistic approach to adherence programmes
5.18.Consider the limited impact of programmes on decision-making
5.19.Examples of successful programmes
5.20.BMS has demonstrated successful collaboration
5.21.Novartis: bridging the gap between different countries
5.22.Adherence programmes can require proactive measures
5.23.It can be effective to pre-empt the reasons for non-adherence
6.TECHNOLOGICAL ADVANCES IN ADHERENCE MANAGEMENT
6.1.Different technologies to enhance patient adherence
6.2.Internet-based medication support
6.3.Reminder services
6.4.Smartphone apps
6.5.Electronic pill dispensers
6.6.Smart pills
6.7.The cost-benefit of new innovations needs to be proven
6.8.Innovative technology may go some way towards addressing adherence but is not a complete solution
7.FUTURE DIRECTION FOR PATIENT ADHERENCE
7.1.How will adherence strategies evolve?
7.2.There are unmet needs for improving adherence
7.3.Innovative approaches to adherence are anticipated
7.4.Improvements in devices and delivery mechanisms would aid adherence
7.5.Recommendations for pharma companies
7.6.Education is vital to improve adherence
7.7.Listen to external stakeholders
7.8.Take a long-term view
7.9.Including outcomes as part of adherence programmes will make them more valuable
7.10.Harness knowledge and experience from external providers
7.11.Early planning will help to guarantee success
